Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XR

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

ADHD

Conditions

ADHD, Autism

Trial Timeline

Sep 1, 2014 → Oct 1, 2016

NCT ID

NCT02255565

About Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XR

Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XR is a approved stage product being developed by Pfizer for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT02255565. Target conditions include ADHD, Autism.

What happened to similar drugs?

9 of 20 similar drugs in ADHD were approved

Approved (9) Terminated (3) Active (10)

✅atomoxetineEli LillyApproved

✅Strattera (atomoxetine)Eli LillyApproved

✅Atomoxetine + placeboEli LillyApproved

✅Atomoxetine Hydrochloride + placeboEli LillyApproved

✅atomoxetine (Strattera)Eli LillyApproved

🔄dasotraline + PlaceboSumitomo PharmaPhase 3

🔄dasotraline 4mgSumitomo PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02255565	Approved	Completed	Sep 1, 2014	Oct 1, 2016	ADHD

Competing Products

20 competing products in ADHD

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Strattera (atomoxetine)	Eli Lilly	Approved	43
Atomoxetine + placebo	Eli Lilly	Approved	43
Atomoxetine Hydrochloride + placebo	Eli Lilly	Approved	43
atomoxetine (Strattera)	Eli Lilly	Approved	43
Atomoxetine + stimulants (any approved ADHD medication)	Eli Lilly	Pre-clinical	26
dasotraline + Placebo	Sumitomo Pharma	Phase 3	40
dasotraline	Sumitomo Pharma	Phase 1	29
dasotraline 4mg	Sumitomo Pharma	Phase 3	40
AZD1446 + AZD1446 + AZD1446 + Placebo	AstraZeneca	Phase 2	35
Placebo + AZD3480 + AZD3480	AstraZeneca	Phase 2	35
MK0249 + Concerta (methylphenidate) + Placebo	Merck	Phase 2	35
Focalin XR	Novartis	Phase 3	40
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo	Novartis	Approved	43
Dexmethylphenidate HCl extended-release capsules	Novartis	Phase 3	40
Methylphenidate hydrochloride	Novartis	Phase 3	40
Focalin XR	Novartis	Phase 3	40
methylphenidate HCl ERCT + Placebo	Pfizer	Approved	35
methylphenidate HCl ERCT	Pfizer	Approved	35
Brexpiprazole	Lundbeck	Phase 1	26